Maridebart cafraglutide MariTide

An experimental long-acting weight-loss drug (also known by the code name MariTide) in human trials, needing only monthly or less-frequent dosing. Early results show substantial weight loss, though it remains unapproved while more trials are completed.

Also known as AMG 133

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial dosing under evaluation

Reported range Phase II trials: monthly subcutaneous dosing, exact doses still being optimized

Route Subcutaneous injection

Frequency Once monthly (trial protocol)

Duration Trial durations of several months to a year

An investigational GIP receptor antagonist/GLP-1 agonist combination antibody (Amgen, also known as MariTide) for obesity, notable for a once-monthly dosing schedule; not an approved product.

Where this comes from Published Phase II clinical trial data (Amgen)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.